Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder

The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. In a Dec. 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) launched its pivotal trial program for...
Streetwise Reports | January 6, 2020 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |

Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress

Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. Amarin Corp. (AMRN:NASDAQ) ADR shares are up sharply today after the com...
Streetwise Reports | July 3, 2019 |

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |

DIAGNOS poised for parabolic move as first of new cardio AI Applications comes to market

DIAGNOS Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) is a Canadian-based healthcare software technology company that pioneered ' C omputer A ssisted R etinal A nalysis' (CARA), applying artificial intelligence to non-invasively test, identify, and classify patients a...
James O'Rourke | May 5, 2020 |

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANG...
Streetwise Reports | October 8, 2019 |

The New Cannabis & CBD Therapy for PTSD

This podcast is part of our StockTalk Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public cannabis marketplace. There are around eight million people in the U...
Stockhouse Media | November 6, 2019 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |

Diagnos increases footprint, and endorsements mount for AI tech that averts illness

Applying Artificial Intelligence (AI) for early detection tests of vascular change in the retina, targeting the diabetes market for vision loss prevention & soon cardiovascular disease. Valuation and Assumptions: Based on due diligence and valuation estimates, Mar...
Fredrick William | June 4, 2020 |

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation

Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. This morning, shares of clinical-stage biotechnology firm Viela Bio Inc. (VIE:NASDAQ) , which is focused on pioneering treatments for autoimmune and...
Streetwise Reports | February 19, 2020 |
1 2 3 4 5 6 7 8